|
New Engl J Med Op Ed article questions wisdom of Medicare 3 year limit on immunusuppressive drugs after transplantation. |
 |
|
NEJM: H.R. 2969 represents a key opportunity to correct an irrational, needlessly wasteful policy that has harmed many U.S. patients. Its passage would achieve three important objectives: protect Medicare's investment in each renal allograft, help bring U.S. kidney-transplant outcomes up to par with those in other developed countries, and most important, save the lives of people with kidney failure.
|